Every Form 4 that BioStem Technologies, Inc. (BSEM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BSEM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BSEM filings page.
BioStem Technologies, Inc. Chief Operating Officer and director Vurst Andrew Smith-Van exercised options to acquire 250,000 common shares at an exercise price of $2 per share on October 7, 2026. His reported direct common-stock holdings after the transaction were 1,789,809 shares. The exercised options were fully vested and exercisable. Other reported direct options covered 114,314 and 23,246 shares at $10.05 per share, and 253,304 shares at $5.50 per share.
BioStem Technologies, Inc. Chief Executive Officer Jason Matuszewski exercised options to acquire 250,000 common shares at a $2.00-per-share exercise price on October 7, 2026. The options were fully vested and exercisable. After the exercise, he directly held 1,553,551 common shares; the reported balance corrects a prior one-share overstatement from an administrative error in reporting an earlier restricted stock unit vesting.
BioStem Technologies, Inc. (BSEM) reported that Chief Financial Officer Brandon Poe exercised previously granted equity awards on September 15, 2026. He converted 1,694 restricted stock units into an equal number of shares of common stock at a reported price of $0.00 per share, increasing his directly held common stock to 58,062 shares after the transaction.
Following this event, Poe continues to hold significant unexercised equity incentives, including options to buy common stock and additional restricted stock units that vest over multi‑year schedules.
BioStem Technologies, Inc. (BSEM) insider Andrew Smith-Van Vurst, a director, Chief Operating Officer and ten percent owner, exercised restricted stock units into common stock on September 15 and September 17, 2026. He converted 7,622 and 9,574 restricted stock units, respectively, into an equal number of common shares at a stated price of $0.00 per share, with corresponding RSU positions disposed of. No open-market purchases or sales are reported, and no Rule 10b5-1 trading plan is indicated. He continues to hold significant equity awards, including multiple option grants and 209,091 restricted stock units tied to future vesting.
BioStem Technologies, Inc. (BSEM) reports that Chief Executive Officer and director Jason Matuszewski exercised restricted stock units into common stock in two transactions. On September 15, 2026, 8,469 restricted stock units converted into 8,469 shares of common stock, and on September 17, 2026, 16,650 restricted stock units converted into 16,650 shares of common stock, all at a stated price of $0.00 per share. The restricted stock unit positions were reduced and the common stock position increased accordingly, with no market purchases or sales reported. No Rule 10b5-1 trading plan is indicated.
Matuszewski continues to hold significant derivative positions, including options to acquire shares of common stock at exercise prices of $2.00, $10.05, and $5.50 per share with expirations between October 24, 2032 and February 11, 2036, as well as restricted stock units representing 363,636 underlying shares, all held directly.
BioStem Technologies, Inc. (BSEM) director Kenneth Howard Warrington Jr reported an award-related equity transaction on September 15, 2026. He exercised 1,694 restricted stock units, each representing a contingent right to one share of common stock, resulting in the acquisition of 1,694 shares of common stock at a stated price of $0.00 per share. Following this transaction, he held 33,928 shares of common stock directly and 6,773 restricted stock units that continue to vest in equal quarterly installments over three years from the grant date of September 15, 2024. He also directly holds stock options covering 7,462 shares of common stock at an exercise price of $1.80 per share, fully vested and exercisable, expiring March 29, 2032. No Rule 10b5-1 trading plan is reported for these transactions.
BioStem Technologies, Inc. (BSEM) reports that Chief Accounting Officer Michael A. Fortunato converted 4,234 restricted stock units into 4,234 shares of common stock on September 15, 2026, at no cash exercise price. After this conversion, he holds 68,664 common shares directly and continues to hold multiple option and restricted stock unit awards. No Rule 10b5-1 trading plan is reported for these transactions.
BioStem Technologies, Inc. (BSEM) reports that Chief Commercial Officer Barry Hassett settled 500 restricted stock units into 500 shares of common stock on September 9, 2026, at a reported price of $0.000 per share, resulting in 5,003 common shares held directly after the transaction. The RSU settlement corresponds to units where each RSU represents a contingent right to receive one share of common stock and vesting occurs in quarterly installments over four years from the December 9, 2024 grant date. Hassett also continues to hold several stock option awards and additional RSUs with various vesting schedules extending through February 2029 and option expirations running between 2035 and 2036, indicating ongoing equity-based compensation. No Rule 10b5-1 trading plan is reported for these transactions.
BioStem Technologies, Inc. (BSEM) director Jodi Ungrodt reported the vesting and exercise of restricted stock units into common stock. On August 27, 2026, 5,647 restricted stock units, each representing a contingent right to one common share, were converted into 5,647 shares of common stock. Following this transaction, Ungrodt directly held 11,295 shares of common stock and no remaining restricted stock units from this grant, which had vested in two installments on May 27, 2026 and August 27, 2026.
BioStem Technologies, Inc. (BSEM) reported that director Mark A. Glickman had 7,671 Restricted Stock Units vest on August 27, 2026. These RSUs were exercised and converted into 7,671 shares of common stock at a reported price of $0.00 per share, reflecting a stock-based compensation event rather than an open-market trade. Following the transactions, Glickman holds 7,671 shares of common stock directly and no remaining RSUs from this grant.
BioStem Technologies, Inc. (BSEM) director Rayna Lesser Hannaway reported the vesting and exercise of 7,671 Restricted Stock Units into 7,671 shares of common stock on August 27, 2026. Each RSU represented a contingent right to one share and vested on that date, with no cash exercise price reported. Following the transaction, Hannaway directly holds 7,671 common shares and no remaining RSUs from this grant.
BioStem Technologies, Inc. (BSEM) director Kenneth Howard Warrington Jr reported an exercise of 5,094 Restricted Stock Units into an equal number of shares of common stock on 2026-08-27. The derivative RSUs were disposed and 5,094 common shares were acquired, bringing his direct common stock holdings to 32,234 shares. He also reports fully vested stock options and additional unvested RSUs that may convert into common stock over time.
BioStem Technologies, Inc. (BSEM) director Steven D. Sonenreich reported the vesting and conversion of 7,671 Restricted Stock Units into 7,671 shares of common stock on August 27, 2026. Each RSU represented a contingent right to receive one common share. Following the transaction, he directly held 7,671 shares of common stock and no remaining RSUs from this grant.
BioStem Technologies, Inc. (BSEM) reported that its Chief Financial Officer, Brandon Poe, exercised 10,634 Restricted Stock Units into an equal number of shares of common stock on August 11, 2026 at a stated price of $0.00 per share, resulting in direct ownership of 56,368 common shares. He continues to hold stock options exercisable for 38,814 common shares at $6.48 per share expiring in 2035 and 117,401 shares at $5.50 per share expiring in 2036, plus additional unvested Restricted Stock Units covering 8,469 and 96,909 underlying common shares that vest over time according to stated schedules.
BioStem Technologies, Inc. (BSEM) reported that Chief Accounting Officer Michael A. Fortunato exercised 970 Restricted Stock Units into 970 shares of Common Stock on August 9, 2026 at $0.00 per share, leaving him with 64,430 directly held common shares. The filing also lists multiple outstanding stock option and RSU awards with various exercise prices and vesting schedules, including options over 200,000 shares at $1.07 expiring August 16, 2027 and additional RSUs over 21,175 and 31,818 underlying shares.